AICIS Rules for Research and Development Introductions

Australia handles cosmetic ingredients through a completely different lens than most makers expect if they've only ever dealt with Health Canada or the EU's CPNP. There's no per-product notification form waiting at the end of your formulation work. Instead, AICIS treats your ingredients as industrial chemicals, and that framework has its own special category for the small-batch experimenting every formulator does before a product ever reaches a shelf.

AICIS in a nutshell

The Australian Industrial Chemicals Introduction Scheme regulates the chemicals used in cosmetics as industrial chemicals, via an Inventory of existing chemicals and a set of introduction categories rather than a single notification per finished product. If a chemical you want to use is already listed on the Inventory, you're generally working from a known, cleared starting point. If it isn't, how you're allowed to bring it into Australia, and in what quantity, depends on which introduction category your situation falls into.

Research and development is one of those categories, and it exists precisely because formulators need room to test, tweak, and trial small batches before committing to a full commercial introduction.

Why R&D gets its own lane

Think about what formulation work actually looks like before a product launches: small test batches, samples sent to a chemist or lab for stability testing, maybe a handful of units for a focus group or dermal testing panel. None of that is a commercial introduction in the sense of a product hitting retail shelves at volume. AICIS's R&D provisions recognize that requiring the same level of scrutiny for a 50 gram lab sample as for a full commercial launch would make ordinary product development prohibitively slow.

The general principle behind R&D introductions is that they're meant for genuinely small-quantity, non-commercial use tied to research or development activity, not as a workaround for bringing a chemical to market without going through the appropriate commercial introduction category. If your "R&D" batch ends up being sold at a market stall, that's not R&D anymore, and treating it as such risks running afoul of the actual introduction category your activity belongs in.

What this means practically for a formulator

If you're developing a new cosmetic product and testing with an ingredient new to your supply chain:

• Confirm first whether the ingredient is already on the AICIS Inventory. If it is, your introduction may already sit in a straightforward category regardless of R&D status.
• If it isn't on the Inventory, and you're at the genuine testing and development stage, look specifically at AICIS's R&D introduction provisions rather than assuming you need the full commercial pathway immediately.
• Keep your quantities and use genuinely proportionate to research purposes. Documentation of what the material was used for, how much was brought in, and who it went to (lab, tester panel, internal formulation trial) supports your position if the introduction category is ever questioned.
• Understand that moving from R&D quantities to commercial sale is a transition point, not something that happens automatically. Once you're ready to sell commercially, you introduce under whichever commercial category actually applies to your situation and quantity.

A rough comparison of the two mindsets

	R&D introduction	Commercial introduction
Purpose	Testing, formulation development, non-commercial trials	Selling a finished product commercially
Typical quantity	Small, proportionate to research needs	Whatever the business actually needs to supply the market
Documentation focus	What it was used for and by whom	Full introduction category requirements for the specific chemical and volume

Why this framework feels unfamiliar if you're used to Canada or the EU

Health Canada's Cosmetic Notification Form is about the finished product, filed after first sale, with INCI names and concentrations. The EU's CPNP works similarly, notification per product through a Responsible Person. AICIS instead sits at the ingredient and chemical level, evaluating what's being introduced into Australian commerce as a chemical, independent of which finished product it ends up in. That's a genuinely different mental model, and it's easy to bring assumptions from a product-notification market and apply them incorrectly to Australia's system.

Because the exact category thresholds, quantity limits, and documentation requirements for R&D introductions can be specific and are worth getting right, this is a case where checking AICIS's current published guidance directly is the safer move rather than relying on general description. Categories and thresholds are the kind of detail that a regulator updates from time to time.

Cosmetic Comply's live market right now is Canada, with the US, EU, and Australia on the roadmap. For makers watching the Australian market while they finish formulation work elsewhere, the practical lesson from AICIS's R&D category carries over regardless of tool: keep your test-stage activity genuinely test-stage, document it as such, and treat the shift to commercial introduction as a deliberate step, not something that happens by default once a product starts selling well.